<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="61569"><DrugName>dusigitumab</DrugName><DrugNamesKey><Name id="42993714">dusigitumab</Name></DrugNamesKey><DrugSynonyms><Name><Value>anti-insulin-like growth factor 1/insulin-like growth factor 2 antibodies (solid tumor), MedImmune</Value></Name><Name><Value>MEDI-573</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>anti-IGF1/IGF2 antibodies (iv infusion, solid tumor), MedImmune</Value></Name><Name><Value>dusigitumab</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18008">MedImmune LLC</CompanyOriginator><CompaniesSecondary><Company id="18008">MedImmune LLC</Company></CompaniesSecondary><CrossReferences><SourceEntity id="61569" type="Drug"><TargetEntity id="655399" type="siDrug">Dusigitumab</TargetEntity></SourceEntity><SourceEntity id="18008" type="Company"><TargetEntity id="4295907119" type="organizationId">Medimmune LLC</TargetEntity></SourceEntity><SourceEntity id="1767" type="ciIndication"><TargetEntity id="D006528" type="MeSH"></TargetEntity><TargetEntity id="88673" type="ORPHANET"></TargetEntity><TargetEntity id="-1116061312" type="omicsDisease"></TargetEntity><TargetEntity id="1973" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3657" type="ciIndication"><TargetEntity id="10055113" type="MEDDRA"></TargetEntity><TargetEntity id="589" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3253" type="Action"><TargetEntity id="2519" type="Mechanism">IGF-2R Inhibitors</TargetEntity><TargetEntity id="3643" type="Mechanism">Anti-IGF-2</TargetEntity></SourceEntity><SourceEntity id="3252" type="Action"><TargetEntity id="3642" type="Mechanism">Anti-IGF-1</TargetEntity><TargetEntity id="1104" type="Mechanism">IGF-1R Inhibitors</TargetEntity><TargetEntity id="2556" type="Mechanism">Anti-CD221 (IGF-1R)</TargetEntity></SourceEntity><SourceEntity id="PTGT-01033" type="ciTarget"><TargetEntity id="183017565234803" type="siTarget">Insulin-like growth factor 1 receptor</TargetEntity><TargetEntity id="381" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01034" type="ciTarget"><TargetEntity id="166602379734823" type="siTarget">Cation-independent mannose-6-phosphate receptor</TargetEntity><TargetEntity id="2913" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1767">Hepatocellular carcinoma</Indication><Indication id="3657">Metastatic breast cancer</Indication><Indication id="3713">Advanced solid tumor</Indication><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="3252">Insulin-like growth factor 1 receptor antagonist</Action><Action id="3253">Insulin-like growth factor 2 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="55685">Anticancer monoclonal antibody</Action><Action id="62254">Anticancer hormone antagonist</Action><Action id="62255">Anticancer protein kinase inhibitor</Action></ActionsSecondary><Technologies><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="740">Infusion</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2018-04-06T08:20:10.000Z</LastModificationDate><ChangeDateLast>2018-04-06T00:00:00.000Z</ChangeDateLast><AddedDate>2008-10-14T15:47:38.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18008" linkType="Company"&gt;MedImmune&lt;/ulink&gt; and parent company &lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt; were developing dusigitumab (MEDI-573), a fully human mAb targeting insulin-like growth factor 1 (IGF-1) and IGF-2,  for the potential treatment of solid tumors, primarily metastatic breast cancer (MBC) [&lt;ulink linkID="952032" linkType="Reference"&gt;952032&lt;/ulink&gt;].  In October 2011, a phase I/II MBC trial was initiated [&lt;ulink linkID="1228871" linkType="Reference"&gt;1228871&lt;/ulink&gt;]. In February 2017, the drug was still listed as being in phase II development for metastatic breast cancer [&lt;ulink linkID="1909620" linkType="Reference"&gt;1909620&lt;/ulink&gt;]. In January 2014, phase III development for MBC was expected to be initiated in 2015 [&lt;ulink linkID="1515725" linkType="Reference"&gt;1515725&lt;/ulink&gt;]. However, by December 2017, dusigitumab development had been discontinued  for reasons of safety and efficacy [&lt;ulink linkID="2002023" linkType="Reference"&gt;2002023&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Dusigitumab was also previously in development for hepatocellular carcinoma (HCC). In December 2011, a phase Ib/II, 5-arm, HCC trial began; however, by September 2012, the trial had been downgraded to a 3-arm phase Ib trial, and only 6 people were eventually enrolled  [&lt;ulink linkID="1252239" linkType="Reference"&gt;1252239&lt;/ulink&gt;]. By January 2013, MBC was the only indication listed as active on AstraZeneca's pipeline [&lt;ulink linkID="1364924" linkType="Reference"&gt;1364924&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Metastatic breast cancer&lt;/subtitle&gt;In January 2014, phase III development for MBC was expected to be initiated in 2015 [&lt;ulink linkID="1515725" linkType="Reference"&gt;1515725&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2011, a randomized, open-label, phase I/II study (&lt;ulink linkID="81306" linkType="Protocol"&gt;NCT01446159&lt;/ulink&gt;; CD-ON-MEDI-573-1030) was initiated in patients with MBC (expected n = 267) in the US, to assess the safety, efficacy, pharmacokinetics and pharmacodynamics of dusigitumab in combination with an aromatase inhibitor compared with an aromatase inhibitor alone. In May 2013, trial completion was expected in  August 2015; by that time, only 187 patients were expected to be enrolled in the trial   [&lt;ulink linkID="1228871" linkType="Reference"&gt;1228871&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hepatocellular carcinoma&lt;/subtitle&gt;In December 2011, a randomized, open-label, phase Ib/II trial (&lt;ulink linkID="83593" linkType="Protocol"&gt;NCT01498952&lt;/ulink&gt;; CD-ON-MEDI-573-1028) was initiated in patients with unresectable or metastatic HCC (expected n = 216) in the US, to assess the safety and efficacy of dusigitumab. At that time, study completion was scheduled for October 2014. However,  in April 2012, the trial was downsized from a 5-arm trial enrolling  216 patients to a 4-arm trial enrolling 138 patients and, in September 2012 it was downsized further to a 3-arm  trial enrolling 9 patients with the phase II portion no longer planned. In May 2013, enrollment had been completed with only 6 patients having been enrolled; at that time, trial completion was  expected later that same month [&lt;ulink linkID="1252239" linkType="Reference"&gt;1252239&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In July 2011, an open label, single arm, dose escalation, phase I trial (&lt;ulink linkID="76719" linkType="Protocol"&gt;NCT01340040&lt;/ulink&gt;, D5621C00006) of dusigitumab began in patients with advanced solid tumors (n=10) in Japan.  The trial was completed in May 2012 [&lt;ulink linkID="1222131" linkType="Reference"&gt;1222131&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2009, a multi-center, open-label, single-arm, dose-escalation, phase I trial (&lt;ulink linkID="39798" linkType="Protocol"&gt;NCT00816361&lt;/ulink&gt;; MI-CP184) was initiated in subjects (n = 43) with advanced solid tumors refractory to  standard therapy in the US. Subjects were to receive a 60-min iv infusion of dusigitumab over 21 days and the primary endpoints were safety, tolerability and  maximum tolerated dose (MTD). The trial was completed in October 2012 [&lt;ulink linkID="1004469" linkType="Reference"&gt;1004469&lt;/ulink&gt;]. In January 2011, preliminary data showed the drug did not  alter glucose homeostasis [&lt;ulink linkID="1162351" linkType="Reference"&gt;1162351&lt;/ulink&gt;]. In March 2012, further data were presented at the 113th Annual Meeting of the ASCPT in National Harbor, MD. A sustained suppression of unbound IGF-1 and -2 in plasma was observed with weekly doses greater than 5 mg [&lt;ulink linkID="1269998" linkType="Reference"&gt;1269998&lt;/ulink&gt;], [&lt;ulink linkID="1272797" linkType="Reference"&gt;1272797&lt;/ulink&gt;]. In June 2012, further data were presented at the 48th ASCO meeting in Chicago, IL.  No DLTs were identified and the MTD was not determined.  Eight patients had stable disease for &amp;gt;/= 12 weeks [&lt;ulink linkID="1299294" linkType="Reference"&gt;1299294&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In  April 2014, preclinical data were presented at the 105th AACR meeting in San Diego, CA. In vitro, dusigitumab potently inhibited the proliferation of several sarcoma cell lines, with Ewing's sarcoma cell lines being the most sensitive.  Dusigitumab in combination with either &lt;ulink linkID="85508" linkType="Drug"&gt;rapamycin&lt;/ulink&gt; or &lt;ulink linkID="59924" linkType="Drug"&gt;AZD-2014&lt;/ulink&gt; significantly enhanced the anti-tumor activity of dusigitumab [&lt;ulink linkID="1539286" linkType="Reference"&gt;1539286&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, preclinical data were presented demonstrating  dusigitumab's inhibition of  IGF-2 activated insulin receptor isoform A (IR-A) signal pathways without cross reactivity to insulin at the 102nd AACR meeting in Orlando, FL [&lt;ulink linkID="1175533" linkType="Reference"&gt;1175533&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2008, preclinical data were presented at the IQPC's Realising the Commercial Potential of Therapeutic Antibodies conference in London, UK. Dusigitumab inhibits phosphorylation and proliferation at low nanomolar concentrations in in vivo mouse models [&lt;ulink linkID="952032" linkType="Reference"&gt;952032&lt;/ulink&gt;]. In April 2009, further data presented at the 100th AACR meeting in Denver, CO, showed that   dusigitumab had potent antitumor efficacy against clone 32 and P12 xenografts. Furthermore, in nude mice at 5 to 20 mg/kg, dusigitumab inhibited the growth of NIH3T3 cells expressing IGF-1, -2 or IGF-1R. [&lt;ulink linkID="997015" linkType="Reference"&gt;997015&lt;/ulink&gt;], [&lt;ulink linkID="997012" linkType="Reference"&gt;997012&lt;/ulink&gt;]. Similar data were published in February 2011 [&lt;ulink linkID="1162579" linkType="Reference"&gt;1162579&lt;/ulink&gt;], [&lt;ulink linkID="1162351" linkType="Reference"&gt;1162351&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2017-12-31T00:00:00.000Z</StatusDate><Source id="2002023" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2017-12-31T00:00:00.000Z</StatusDate><Source id="2002023" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-12-31T00:00:00.000Z</StatusDate><Source id="2002023" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2013-01-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2011-12-23T00:00:00.000Z</StatusDate><Source id="1252239" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2009-03-31T00:00:00.000Z</StatusDate><Source id="1004469" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2011-07-31T00:00:00.000Z</StatusDate><Source id="1222131" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2011-10-04T00:00:00.000Z</StatusDate><Source id="1228871" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2008-10-30T00:00:00.000Z</StatusDate><Source id="952032" type="CONFERENCE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01033"><Name>Insulin-like growth factor 1 receptor</Name><SwissprotNumbers><Swissprot>P08069</Swissprot><Swissprot>P24062</Swissprot><Swissprot>Q05688</Swissprot><Swissprot>Q29000</Swissprot><Swissprot>Q60751</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01034"><Name>Insulin-like growth factor 2 receptor</Name><SwissprotNumbers><Swissprot>P08169</Swissprot><Swissprot>P11717</Swissprot><Swissprot>Q07113</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="1185707" number="WO-2011046871" title="Quantification of IR-A and IR-B for tumor classification"/><PatentFamily id="1833417" number="WO-2008152422" title="Binding proteins specific for insulin-like growth factors and uses thereof"/><PatentFamily id="2301431" number="WO-2012068148" title="Regimens for treatments using anti-IGF antibodies"/><PatentFamily id="2805260" number="WO-2014150840" title="Methods of treating breast cancer"/><PatentFamily id="2960619" number="WO-2015095329" title="Compositions and methods for treating sarcoma"/><PatentFamily id="700403" number="WO-2007070432" title="Binding proteins specific for insulin-like growth factors and uses thereof"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amgen Inc" id="14109"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"/><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mayo Clinic Foundation" id="21111"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Silence Therapeutics plc" id="22356"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Exelixis Inc" id="22676"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>